IDH3A and central nervous system cancer: The systematic review and meta-analysis conducted by Suh et al. [91] for IDH (isocitrate dehydrogenase) mutation prediction in glioma patients with the help of imaging radiomics data summarizes: Compared to IDH-wildtype glioma, IDH-mutant glioma consistently displayed less aggressive imaging characteristics.